Below are copies of presentations given by Lonza representatives.
For a list of Lonza's archived posters, click here.
|
2009 presentations |
 |
| Potelligent CHOK1SV - Alison Porter |
1235 Kb |
 |
|
| Improving GS-CHO Cell Line Selection: Reducing Time to Clinic - Dr Adrian Haines |
5871 Kb |
 |
|
| | |
2008 Presentations |
|
| Antibody Manufacture: The Search of "Desirable" Cell Lines - A. Porter |
418 Kb |
|
|
| Important Topics in the Expression of Recombinant Antibodies from CHO Cells - R. Young |
1104 Kb |
|
|
| Improving process performance by increasing process robustness - A. Mohindra |
747 Kb |
|
|
| Improving process performance by increasing process robustness; controlling the physiochemical environment of the culture - C. Jaques |
898 Kb |
|
|
| Selection Strategies for Isolating "Desirable" GS-CHO Cell Lines - A. Porter |
470 Kb |
|
|
| | |
2007 Presentations
|
|
|
| The use of FACS for the selection of cell lines with superior productivity characteristics - Jonathan Welsh |
967 Kb |
|
|
|
| Behaviour of Cell Lines in a Selection - Alison Poter, March 2007 |
554 Kb |
|
|
|
| Behaviour of Cell Lines in a Selection Strategy - Alison Porter, October 2007 |
499 Kb |
|
|
|
| Cell Line Creation: Behaviour of Cell Lines in a selection strategy - Alison Porter, December 2007 |
507 Kb |
|
|
|
| Novel approaches for the improvement of transient expression using CHO cells - Alison J. Mastrangelo |
398 Kb |
|
|
|
|
2006 Presentations
|
|
|
| Rapid Production of Antibodies by GS-CHO Pools - Catherine Brown |
316 Kb |
|
|
|
| Improving Cell Line Selection Strategies - Alison Porter |
325 Kb |
|
|
|
|
2005 presentations |
|
| Application of Disposable Technologies in Biopharmaceutical Manufacturing - Martin Wrankmore. Presented at IBC Biopharm Manufacturing and Distribution Summit, 13 December 05 |
4086 Kb |
|
|
|
| Suitability and Stability of Cell Lines for Manufacturing Antibodies, Experience with GS Cell Lines - Andy Racher. Presented at IBC Cell Line Development and Engineering, 14 November 05 |
295 Kb |
|
|
|
| The Importance of Developing a High Yield of Product - John Birch. Presented at European Antibody Congress 2005, 03 November 05 |
729 Kb |
|
|
|
| Future Perspectives of Antibody Manufacturing - John Birch. Presented at BioProduction, 25 October 05 |
625 Kb |
|
|
|
| Development of Robust and Scalable Processes - Andrew Racher. Presented at IBC's Clinical Trial Supply of Biolgics, 05 October 05 |
170 Kb |
|
|
|
| Purification Scale-Up and Technology Transfer for 20,000 L cGMP Facility - David Page. Presented at IBC's BioProcess International World Conference & Exposition, 21 September 05 |
521 Kb |
|
|
|
| Challenges and Opportunities in the Large Scale Production of Therapeutic Proteins - John Birch. Presented at ESACT, 07 June 05 |
777 Kb |
|
|
|
| Toward Stronger Gene Expression: A Promoter's Tale - Stephan Kalwy. Presented at ESACT, 07 June 05 |
812 Kb |
|
|
|
| Efficient generation of highly productive cell lines utilising the Glutamine Synthetase (GS) Gene Expression System for high level protein expression in CHO cells - Robert Young. Presented at the 4th International Congress on Recombinant Antibodies, 31 May 05 |
1099 Kb |
|
|
|
| Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting - Andy Racher. Presented Wilbio's Antibodies & Recombinant Proteins, 22 May 05 |
822 Kb |
|
|
|
| Upstream Mammalian Cell Processing - Challenges and Prospects - John Birch. Presented at BioProcess International, 11 April 05 |
567 Kb |
|
|
|
| Strategies for the Purification of High Titre, High Volume Mammalian Cell Culture Batches - Martin Smith. Presented at BioProcess International, 11 April 05 |
953 Kb |
|
|
|
| Rapid Selection of CHO Cell Lines Using the Glutamine Synthetase (GS) Expression System for high level protein production - Andrew Racher. Presented at IBC's Antibody Production & Downstream Processing, 09 March 05 |
612 Kb |
|
|
|
| A Case Study on the Application of Disposable Technologies in cGMP Manufacturing Processes for a Therapeutic Antibody - Martin Wrankmore. Presented at Biologicals Manufacturing Summit, 23 February 05 |
1275 Kb |
|
|
|
|
2004 presentations |
|
| Effective Engineering Partnership - Co-presented by Lonza and Parsons |
2389 Kb |
|
|
|
| Approaches to Improving the Performance of Mammalian Cell Cultures for Protein Production - Robert Gay |
571 Kb |
|
|
|
| Development of high-yielding chemically defined and animal component-free generic processes using GS cell lines. - David Mainwaring |
142 Kb |
|
|
|
| Recent Improvements to Lonza's Glutamine Synthetase (GS) Gene Expression System - Robert Gay |
834 Kb |
|
|
|
| Tools and Procedures of Process Transfer- Mark Davis |
948 Kb |
|
|
|
| Evaluation of an alkali stable Protein A matrix versus Protein A Sepharose Fast Flow and considerations on process scale-up to 20,000L. - Simon C.B. Jones & Martin P. Smith |
1075 Kb |
|
|
|
| Mammalian Cell Culture: Current Status, Future Prospects - John Birch |
454 Kb |
|
|
|
| Optimisation of upstream processes for antibody production from mammalian cell culture - John Birch |
266 Kb |
|
|
|
| Creation of High Yielding Cell Lines for Successful Large-Scale Production - Robert Gay |
576 Kb |
|
|
|
| Focus on Aggregation and Conformational Changes: Significance of Changes and Characterisation - Mike Davies |
518 Kb |
|
|
|
| Developing Highly Productive Cell Lines and Cell Culture Processes for Producing Therapeutic Antibodies - Robert Gay |
495 Kb |
|
|
|
| WORKSHOP: GS Gene Expression System: GS, Biochemical Comparability, and Cell Line Stability - Andrew Racher |
379 Kb |
|
|
|
| Optimisation of Cell Culture Processes for the Production of Therapeutic Monoclonal Antibodies - John Birch |
287 Kb |
|
|
|
| Establishment of Cell Lines for Manufacturing Recombinant Antibodies - Andrew Racher |
303 Kb |
|
|
|
| The Influence of Scale of Operation on Purification Process Design - J. Davies |
476 Kb |
|
|
|
| A Case Study on the Application of Disposable Technologies in cGMP Manufacturing Processes for a Therapeutic Antibody - Jerry Tong |
707 Kb |
|
|
|
| Rapid Selection of High-Yielding GS-CHO Cell Lines Using the GS Expression System in a Protein-Free, Fully Chemically Defined, Animal Component-Free Process - David Mainwaring |
313 Kb |
|
|
|
| The Influence of Scale of Operation on Purification Process Design - Jim Davies |
476 Kb |
|
|
|
| Structured Continuous Improvement to Achieve Operational Excellence - Martin Wrankmore |
321 Kb |
|
|
|
| Small and Large Molecule Bioproduction by Mammalian and Microbial Fermentation - Hans-Peter Meyer |
727 Kb |
|
|
|
| Process Development for Monoclonal Antibodies - Andrew Racher |
400 Kb |
|
|
|
| Case Study: Strategy to improve fermentation conditions for improved yields from mammalian cell processes - John Birch |
515 Kb |
|
|
|
| Process Validation from a Contract Manufacturer's Point of View - Mark Davis |
95 Kb |
|
|
|
| An evaluation of Protein A and Non-Protein A methods for the recovery of monoclonal antibodies and considerations for process scale-up - Martin Smith |
665 Kb |
|
|
|
|
|
|
